Company Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
0.7101 ^USD	0.00%		+5.12%	-1.38%

May. 01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
Apr. 29	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Companyâs initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Companyâs product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.

Number of employees: 13

Managers	Title	Age	Since
Hans Schambye CEO	Chief Executive Officer	59	10-12-31
Jonathan Freve DFI	Director of Finance/CFO	46	20-03-31
Anders Pedersen COO	Chief Operating Officer	64	19-12-31
Stephanie Oestreich PRN	Corporate Officer/Principal	50	22-01-04
Garrett Winslow LAW	General Counsel	45	21-05-10

Members of the board	Title	Age	Since
Carl Samuel Goldfischer CHM	Chairman	65	19-12-31
Chau Khuong BRD	Director/Board Member	48	17-12-31
David Shapiro BRD	Director/Board Member	69	20-05-18
Amit Munshi BRD	Director/Board Member	56	20-05-18
Søren Møller BRD	Director/Board Member	56	19-12-31
Anne Prener BRD	Director/Board Member	66	21-01-07
Hans Schambye CEO	Chief Executive Officer	59	10-12-31
Jayson Dallas BRD	Director/Board Member	56	20-11-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,112,697	23,910,071 ( 88.19 %)	0	88.19 %

Name	Equities	%	Valuation
Novo Holdings A/S (Investment Company) 9.213 %	2,497,791	9.213 %	2 M $
Erik Otto 6.639 %	1,800,000	6.639 %	1 M $
Sunstone Capital A/S 5.443 %	1,475,802	5.443 %	1 M $
Bay City Capital LLC 3.834 %	1,039,468	3.834 %	810 785 $
Renaissance Technologies LLC 1.501 %	406,968	1.501 %	317 435 $
Vanguard Global Advisers LLC 0.8159 %	221,200	0.8159 %	172 536 $
Geode Capital Management LLC 0.7684 %	208,333	0.7684 %	162 500 $
Bridgeway Capital Management LLC 0.4540 %	123,100	0.4540 %	96 018 $
Two Sigma Securities LLC 0.3575 %	96,927	0.3575 %	75 603 $
Citadel Securities GP LLC 0.2672 %	72,433	0.2672 %	56 498 $

Galecto, Inc.

75 State Street Suite 100

02109, Boston

http://www.galecto.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7101 USD

Average target price

6 USD

Spread / Average Target

+744.95%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
GALECTO, INC.	-1.38%	19.25M
REGENERON PHARMACEUTICALS, INC.	+10.44%	107B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	106B
ARGENX SE	+6.72%	23.47B
BIONTECH SE	-13.89%	21.9B
GENMAB A/S	-6.64%	18.77B
WUXI APPTEC CO., LTD.	-37.26%	17.85B
BEIGENE, LTD.	-10.98%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.41B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.86B

Bio Therapeutic Drugs